Research finds interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination doubles antibody response.
A world-first genetic test, developed in Manchester, that could save the hearing of hundreds of babies each year has been successfully piloted in the NHS.
The results of the world’s first Phase 3 trials, of a new drug Gefapixant, show that it can ease the often distressing symptoms of chronic cough, with minimal side effects.
The NIHR Immune Mediated Inflammatory Disease (IMID) BioResource recently hit a major recruitment milestone of 2000 volunteers, thanks to the collaborative effort of centres across England.